The Stark Truth about Breast Cancer ScreeningOur Mission

SignPost was founded to create BreastDefense, a new class of precise diagnostic tests for breast cancer, based on recent advances in molecular medicine.

SignPost is at the forefront, globally, in accelerating the move toward precision medicine.

The Troublesome Truth About Breast Cancer

For breast cancer, the most common screening method - mammography-does not lead to the identification of aggressive tumors any earlier than in non- screened populations.  Alarmingly inaccurate mammograms lead to years of needless psychological trauma, chemo, radiation, and disfiguring surgery.

What many women don't realize is the potential harm of overdiagnosis, not to be confused with false positive. It is when a mammogram detects non-invasive or benign cancer which is unlikely to cause a problem. Currently, there is no way to tell, and treatment can lead to surgery, chemo, or radiation that is unnecessary.

The story doesn't get any better for survivors of breast cancer in remission. Survivors are subjected to repeated tests to monitor remission.

Women Deserve Better - Survivors Deserve Better

BreastDefense can detect all major sub-types of breast cancer (for stages 1-4) with a test that balances 98.5% for both sensitivity and specificity. BreastDefense will distinguish benign cells from those containing invasive breast cancer. BreastDefense aims to achieve the same degree of accuracy in monitoring remission.

Once breast cancer treatments are completed, survivors want to monitor remission.

It can be a time of worry for women who fear the cancer could come back.

BreastDefense, an easy and accurate blood test will put these fears at bay. It will eliminate the need for inaccurate tests that can do more harm than good.